BiotechTube
Exogenus Therapeutics

Exogenus Therapeutics

Coimbra, Portugal· Est.
exogenus-t.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10.6M

Overview

Exogenus Therapeutics is a private, pre-clinical stage biotech pioneering exosome-based therapeutics. Its core technology involves isolating and preconditioning small extracellular vesicles from umbilical cord blood mononuclear cells to produce a product with anti-inflammatory, immunomodulatory, and regenerative properties. The company has secured key international patents, partnered with Lonza for GMP process development, and is advancing its lead candidate, Exo-101, toward clinical trials targeted for 2027. Exogenus operates a collaborative R&D model to expand its pipeline and applications.

Regenerative MedicineInflammatory Diseases

Technology Platform

Proprietary platform for isolating and preconditioning small extracellular vesicles (exosomes) from umbilical cord blood mononuclear cells, yielding a product with anti-inflammatory, immunomodulatory, and regenerative properties.

Funding History

2
Total raised:$10.6M
Series A$8.5M
Seed$2.1M

Opportunities

The global market for regenerative medicine and anti-inflammatory therapies is vast and growing.
Exogenus's patented, scalable platform and GMP partnership position it to capture value in this space through its lead program and potential expansion into new indications.
Strong IP in major markets (US, EU, Asia) enables global commercial exploitation.

Risk Factors

The company faces significant risks including the unproven clinical efficacy and safety of its exosome therapy in humans, the evolving and complex regulatory pathway for EV-based products, and dependence on raising capital to fund expensive clinical trials.
Competition in the exosome field is intensifying.

Competitive Landscape

Exogenus operates in the competitive and fast-evolving extracellular vesicle therapeutics landscape, competing with other biotechs like Evox Therapeutics, Codiak BioSciences, and Avalon GloboCare. Its differentiation lies in its specific umbilical cord blood source, preconditioning technology, and a multifactorial mode of action targeting inflammation and regeneration.

More companies in Drug Delivery & Formulation →More companies in Portugal →